Background: Fenoldopam mesylate is a selective agonist of DA-1 receptors. It is currently
used for the in-hospital treatment of severe hypertension. DA-1 receptors have high density in renal parenchyma
and for this reason, a possible reno-protective role of Fenoldopam mesylate was investigated.
Methods: We examined all studies regarding the role of Fenoldopam mesylate in Acute Kidney Injury
(AKI); particularly, those involving post-surgical patients, intensive care unit patients and contrastinduced
Results and Conclusion: Fenoldopam mesylate was found to be effective in reducing the onset of
postoperative AKI, when used before the development of the kidney damage. Positive results were
also obtained in the management of intensive care unit patients with AKI, although the clinical studies
investigated were few and conducted on small samples. Conflicting results were achieved in contrastinduced
Keywords: Fenoldopam mesylate, post-operative acute kidney injury, contrast-induced nephropathy, Intensive care unit-acute kidney injury, DA-1 receptor, dopamine, chronic kidney disease.
Rights & PermissionsPrintExport